Although peripheral DOPA decarboxylase inhibitors (benserazide, carbidopa) are included in the common PD medications, they cannot impede an endothelial conversion of L-DOPA once the drug is transported to the abluminal side of the vessels. This evidence concerns the gene DDC and Parkinson disease.